Application of enzyme-linked immunosorbent assay in cancer detection

Abstract

The enzyme-linked immunosorbent assay (ELISA) has emerged as an indispensable method in the realm of cancer detection., serving as a significant factor in the timely identification, prediction, and surveillance of many forms of cancer. ELISA as a highly sensitive immunological assay, utilizes the binding affinity between antibodies and antigens to detect and quantify cancer-associated biomolecules, such as tumor markers, oncogenic proteins, and specific antibodies. The recently adopted methodology facilitates the identification of cancer-associated biomarkers in various types of samples, such as plasma, urine, and tissue extracts. In the context of cancer diagnosis, ELISA aids in the early detection of malignancies by detecting cancer-specific biomarkers at low concentrations, allowing for timely intervention and improved patient outcomes. This research provides a concise overview of the multifaceted applications of ELISA in the field of oncology, especially in electrochemical ELISA and gold nanoparticle–based ELISA. It discusses the diverse biomarkers employed, and elucidates its significance in cancer research and clinical practice.